{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:47:50Z","timestamp":1793828870012,"version":"4.6.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI068635"],"award-info":[{"award-number":["UM1AI068635"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI068614"],"award-info":[{"award-number":["UM1AI068614"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI068618"],"award-info":[{"award-number":["UM1AI068618"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI068635"],"award-info":[{"award-number":["UM1AI068635"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93019C00050"],"award-info":[{"award-number":["75N93019C00050"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Vaccine-induced neutralizing antibodies (nAbs) are key biomarkers considered to be associated with vaccine efficacy. In United States government-sponsored phase 3 efficacy trials of COVID-19 vaccines, nAbs are measured by two different validated pseudovirus-based SARS-CoV-2 neutralization assays, with each trial using one of the two assays. Here we describe and compare the nAb titers obtained in the two assays. We observe that one assay consistently yielded higher nAb titers than the other when both assays were performed on the World Health Organization\u2019s anti-SARS-CoV-2 immunoglobulin International Standard, COVID-19 convalescent sera, and mRNA-1273 vaccinee sera. To overcome the challenge this difference in readout poses in comparing\/combining data from the two assays, we evaluate three calibration approaches and show that readouts from the two assays can be calibrated to a common scale. These results may aid decision-making based on data from these assays for the evaluation and licensure of new or adapted COVID-19 vaccines.<\/jats:p>","DOI":"10.1038\/s41598-021-03154-6","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T06:03:55Z","timestamp":1639461835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation"],"prefix":"10.1038","volume":"11","author":[{"given":"Yunda","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Borisov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia Jin","family":"Kee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay N.","family":"Carpp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Wrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suqin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Sarzotti-Kelsoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene","family":"McDanal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando","family":"Pajon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Posavad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Karuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Juliana","family":"McElrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos J.","family":"Petropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Montefiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"key":"3154_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.7326\/M21-0111","volume":"174","author":"M Connors","year":"2021","unstructured":"Connors, M., Graham, B. S., Lane, H. C. & Fauci, A. S. SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn. Ann. Int. Med. 174, 687\u2013690 (2021).","journal-title":"Ann. Int. Med."},{"key":"3154_CR2","unstructured":"McGill COVID19 Vaccine Tracker Team COVID-19 Vaccine Tracker. https:\/\/covid19.trackvaccines.org\/ Last updated 5 Mar, 2021. Access date 8 Mar, 2021."},{"key":"3154_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N Engl. J. Med."},{"key":"3154_CR4","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet (2020)."},{"key":"3154_CR5","unstructured":"Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. (2020)."},{"key":"3154_CR6","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S Vaccine against Covid-19. N Engl. J. Med. 384, 2187\u20132201 (2021).","journal-title":"N Engl. J. Med."},{"key":"3154_CR7","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","volume":"385","author":"PT Heath","year":"2021","unstructured":"Heath, P. T. et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N Engl. J. Med. 385, 1172\u20131183 (2021).","journal-title":"N Engl. J. Med."},{"key":"3154_CR8","unstructured":"US Food and Drug Administration FDA Approves First COVID-19 Vaccine: Approval Signifies Key Achievement for Public Health. FDA News Release. Aug 23, 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-covid-19-vaccine. Accessed 25 Aug  2021"},{"key":"3154_CR9","unstructured":"US Food and Drug Administration COVID-19 Vaccines. COVID-19 Vaccines Authorized for Emergency Use. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/covid-19-vaccines#news Last updated 11 Mar, 2021. Accessed 17 Mar 2021."},{"key":"3154_CR10","unstructured":"World Health Organization Coronavirus Disease (COVID-19): COVID-19 vaccine EUL issued. Available at https:\/\/extranet.who.int\/pqweb\/vaccines\/covid-19-vaccines Access date 15 Jul, 2021. (2021)."},{"key":"3154_CR11","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, and Center for Biologics Evaluation and Research. Emergency Use Authorization for Vaccines to Prevent COVID-19: Guidance for Industry. Appendix 2: pp 18\u201322. Issued on 25 May, 2021. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/emergency-use-authorization-vaccines-prevent-covid-19."},{"key":"3154_CR12","unstructured":"World Health Organization ADDENDUM to Considerations for Evaluation of COVID-19 Vaccines for Prequalification or Emergency Use Listing. Considerations for evaluation of modified COVID-19 vaccines: Points to consider for manufacturers of COVID-19 vaccines. version 12 Mar, 2021. Available at https:\/\/extranet.who.int\/pqweb\/sites\/default\/files\/documents\/Addendum_Evaluation_Modified_Covid-19%20Vaccine.pdf Access date 15 Jul, 2021. (2021)."},{"key":"3154_CR13","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.cmi.2021.08.005","volume":"27","author":"R Dal-Re","year":"2021","unstructured":"Dal-Re, R. & Caplan, A. L. Current COVID-19 vaccine trials in high-income countries: are placebo-controlled trials ethical?. Clin. Microbiol. Infect. 27, 1565\u20131567 (2021).","journal-title":"Clin. Microbiol. Infect."},{"key":"3154_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/1740774520988244","volume":"18","author":"TR Fleming","year":"2021","unstructured":"Fleming, T. R., Krause, P. R., Nason, M., Longini, I. M. & Henao-Restrepo, A. M. M. COVID-19 vaccine trials: The use of active controls and non-inferiority studies. Clin. Trials 18, 335\u2013342 (2021).","journal-title":"Clin. Trials"},{"key":"3154_CR15","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","volume":"17","author":"SA Plotkin","year":"2010","unstructured":"Plotkin, S. A. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17, 1055\u20131065 (2010).","journal-title":"Clin. Vaccine Immunol."},{"key":"3154_CR16","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/cis238","volume":"54","author":"SA Plotkin","year":"2012","unstructured":"Plotkin, S. A. & Gilbert, P. B. Nomenclature for immune correlates of protection after vaccination. Clin. Infect. Dis. 54, 1615\u20131617 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"3154_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/B978-0-323-35761-6.00003-1","volume-title":"Plotkin's Vaccines","author":"SA Plotkin","year":"2018","unstructured":"Plotkin, S. A. & Gilbert, P. B. Chapter three: correlates of protection. In Plotkin\u2019s Vaccines 7th edn (eds Plotkin, S. A. et al.) 35\u201340 (Elsevier, Inc., Philadelphia, PA, 2018).","edition":"7"},{"key":"3154_CR18","doi-asserted-by":"publisher","first-page":"e02107","DOI":"10.1128\/JCM.02107-20","volume":"58","author":"A Addetia","year":"2020","unstructured":"Addetia, A. et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. J. Clin. Microbiol. 58, e02107 (2020).","journal-title":"J. Clin. Microbiol."},{"key":"3154_CR19","doi-asserted-by":"publisher","unstructured":"Cromer, D. et al. Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC) trial. https:\/\/doi.org\/10.1101\/2021.06.29.21259504. medRxiv, 2021.2006.2029.21259504 Accessed 2 Jul 2021.","DOI":"10.1101\/2021.06.29.21259504"},{"key":"3154_CR20","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423\u20134428 (2021).","journal-title":"Vaccine"},{"key":"3154_CR21","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","volume":"27","author":"S Feng","year":"2021","unstructured":"Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 27, 2032\u20132040,\u00a0https:\/\/doi.org\/10.1038\/s41591-021-01540-1 (2021).","journal-title":"Nat. Med."},{"key":"3154_CR22","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1016\/j.cell.2021.05.040","volume":"184","author":"X He","year":"2021","unstructured":"He, X. et al. Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques. Cell 184, 3467\u20133473. https:\/\/doi.org\/10.1016\/j.cell.2021.05.040 (2021).","journal-title":"Cell"},{"key":"3154_CR23","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211. https:\/\/doi.org\/10.1038\/s41591-021-01377-8 (2021).","journal-title":"Nat. Med."},{"key":"3154_CR24","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","volume":"590","author":"K McMahan","year":"2021","unstructured":"McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630\u2013634 (2021).","journal-title":"Nature"},{"key":"3154_CR25","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1126\/science.abc6284","volume":"369","author":"J Yu","year":"2020","unstructured":"Yu, J. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369, 806\u2013811 (2020).","journal-title":"Science"},{"key":"3154_CR26","doi-asserted-by":"publisher","unstructured":"Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science, eab3435. https:\/\/doi.org\/10.1126\/science.abm3425 (2021).","DOI":"10.1126\/science.abm3425"},{"key":"3154_CR27","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397, 881\u2013891 (2021).","journal-title":"Lancet"},{"key":"3154_CR28","unstructured":"US Food and Drug Administration Q2 (R1) Validation of Analytical Procedures: Text and Methodology. March 1995. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/q2-r1-validation-analytical-procedures-text-and-methodology Access date: 5 Aug 2021. Content current as of: 6 Apr 2019."},{"key":"3154_CR29","unstructured":"European Medicines Agency ICH Q2 (R1) Validation of analytical procedures: text and methodology. Last update: 1\/6\/1995. Available at: https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/ich-q-2-r1-validation-analytical-procedures-text-methodology-step-5_en.pdf.  Accessed 8 June 2021."},{"key":"3154_CR30","unstructured":"Mattiuzzo, G. et al. Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody. 2020, WHO Expert Committee on Biological Standardization. WHO\/BS\/2020.2403. (2020)."},{"key":"3154_CR31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215\u2013220 (2020).","journal-title":"Nature"},{"key":"3154_CR32","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"3154_CR33","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280 (2020).","journal-title":"Cell"},{"key":"3154_CR34","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S0140-6736(21)00527-4","volume":"397","author":"PA Kristiansen","year":"2021","unstructured":"Kristiansen, P. A. et al. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet 397, 1347\u20131348 (2021).","journal-title":"Lancet"},{"key":"3154_CR35","unstructured":"World Health Organization Weekly epidemiological update on COVID-19 - 10 August 2021. Edition 52. 10 Aug, 2021 | Emergency Situational Updates. Available here: https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19---10-august-2021. Accessed Aug 13 2021."},{"key":"3154_CR36","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.chom.2021.03.002","volume":"29","author":"X Shen","year":"2021","unstructured":"Shen, X. et al. SARS-CoV-2 variant B117 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe 29, 529\u2013539 (2021).","journal-title":"Cell Host Microbe"},{"key":"3154_CR37","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1126\/science.272.5259.263","volume":"272","author":"L Naldini","year":"1996","unstructured":"Naldini, L. et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263\u2013267 (1996).","journal-title":"Science"},{"key":"3154_CR38","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson, L. A. et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl. J. Med. 383, 1920\u20131931 (2020).","journal-title":"N Engl. J. Med."},{"key":"3154_CR39","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","volume":"383","author":"EJ Anderson","year":"2020","unstructured":"Anderson, E. J. et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl. J. Med. 383, 2427\u20132438 (2020).","journal-title":"N Engl. J. Med."},{"key":"3154_CR40","unstructured":"National Institute for Biological Standards and Control (NIBSC) Instructions for use of First WHO International Standard for anti-SARS-CoV-2 Immunoglobulin (Version 3.0, Dated 17\/12\/2020) NIBSC code: 20\/136 https:\/\/www.nibsc.org\/science_and_research\/idd\/cfar\/covid-19_reagents.aspx Access date Jul 29, 2021."},{"key":"3154_CR41","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1002\/sim.5446","volume":"31","author":"Y Huang","year":"2012","unstructured":"Huang, Y., Huang, Y., Moodie, Z., Li, S. & Self, S. Comparing and combining data across multiple sources via integration of paired-sample data to correct for measurement error. Stat. Med. 31, 3748\u20133759 (2012).","journal-title":"Stat. Med."},{"key":"3154_CR42","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2307\/2532051","volume":"45","author":"LI Lin","year":"1989","unstructured":"Lin, L. I. A concordance correlation coefficient to evaluate reproducibility. Biometrics 45, 255\u2013268 (1989).","journal-title":"Biometrics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03154-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03154-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03154-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T13:31:34Z","timestamp":1670074294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03154-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,14]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["3154"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-03154-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.09.09.21263049","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-862572\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,14]]},"assertion":[{"value":"15 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23921"}}